Chronic Myeloproliferative Disorders Completed Phase 2 Trials for Fludarabine (DB01073)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00053989Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic AnemiaTreatment
NCT00006379Non-Ablative Allo HSCT For Hematologic Malignancies or SAATreatment
NCT00134004Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerTreatment
NCT00346359Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid CancerTreatment
NCT00589563Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological CancerSupportive Care
NCT00806767Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological CancerTreatment